Showing results (51-60 of 59) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Neurology|November 23, 2018
High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapyPhilipp Albrecht, Alexander Jansen, John-Ih Lee, et al.Molecular Microbiology|May 6, 2011
The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sitesJasmin Strotmeier, Shenyan Gu, Stephan Jutzi, et al.Annals of Neurology|May 4, 2004
Clinical impact of antibody formation to botulinum toxin A in childrenJochen Herrmann, Katrin Geth, Volker Mall, et al.Proceedings of the National Academy of Sciences of the United States of America|December 23, 2006
Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor conceptAndreas Rummel, Timo Eichner, Tanja Weil, et al.The Biochemical Journal|August 14, 2010
Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent mannerJasmin Strotmeier, Kwangkook Lee, Anne K Völker, et al.Journal of Neurology|October 4, 2022
Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxinHarald Hefter, Dietmar Rosenthal, Alexander Jansen, et al.Proceedings of the National Academy of Sciences of the United States of America|October 6, 2010
SNARE tagging allows stepwise assembly of a multimodular medicinal toxinFrédéric Darios, Dhevahi Niranjan, Enrico Ferrari, et al.Annals of Clinical and Translational Neurology|December 1, 2020
Long-term adherence and response to botulinum toxin in different indicationsJohn-Ih Lee, Alexander Jansen, Sara Samadzadeh, et al.Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|March 16, 2019
Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patientsAnna Kutschenko, Jasmin Weisemann, Katja Kollewe, et al.Pageof 6